Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in Vietnamese healthcare workers

Châu, Nguyễn Văn Vĩnh; Nguyet, Lam Anh; Truong, Nguyen Thanh; Toan, Le Mau; Dung, Nguyen Thanh; Hung, Le Manh; Nhan, Mai Thanh; Man, Dinh Nguyen Huy; Ngoc, Nghiêm My; Thao, Huynh Phuong; Tu, Tran Nguyen Hoang; Kim, Huynh; Hung, Do Thai; Ny, Nguyen Thi Han; Thanh, Le Kim; Anh, Nguyen To; Hong, Nguyen Thi Thu; Nhu, Le Nguyen Truc; Yen, Lam Minh; Choisy, Marc; Thanh, Tran Tan; Thwaites, Guy; Tan, Le Van

doi:10.1101/2021.07.08.21260162

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody studies showed that among individuals who had no previous infections, IgG antibody levels were maximized approximately 4 weeks after the first dose and 2 weeks after the second dose for mRNA vaccines (104-106). Similarly, neutralizing antibodies were maximized approximately 28 days after the first dose and 14 days after the second dose of the AstraZeneca vaccine (107,108). Therefore, in any future, efficacy research focused on these vaccines, outcomes should be recorded during this period to determine the maximum possible VE.…”

Section: Time After Vaccinationmentioning

confidence: 99%

Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review

Reynolds,

Dewey,

Asfour

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

The purpose of this systematic review was to report on the vaccine efficacy (VE) of three SARS-CoV-2 vaccines approved by Health Canada: Pfizer BioNTech, Moderna, and AstraZeneca. Four databases were searched for primary publications on population-level VE. Ninety-two publications matched the inclusion criteria, and the extracted data were separated by vaccine type: mRNA vaccines (Pfizer and Moderna) and the AstraZeneca vaccine. The median VE for PCR-positive patients and various levels of clinical disease was determined for the first and second doses of both vaccine types against multiple SARS-CoV-2 variants. The median VE for PCR-positive infections against unidentified variants from an mRNA vaccine was 64.5 and 89%, respectively, after one or two doses. The median VE for PCR-positive infections against unidentified variants from the AstraZeneca vaccine was 53.4 and 69.6%, respectively, after one or two doses. The median VE for two doses of mRNA for asymptomatic, symptomatic, and severe infection against unidentified variants was 85.5, 93.2, and 92.2%, respectively. The median VE for two doses of AstraZeneca for asymptomatic, symptomatic, and severe infection against unidentified variants was 69.7, 71, and 90.2%, respectively. Vaccine efficacy numerically increased from the first to the second dose, increased from the first 2 weeks to the second 2 weeks post-vaccination for both doses, but decreased after 4 months from the second dose. Vaccine efficacy did not differ by person's age.

show abstract

Section: Time After Vaccinationmentioning

confidence: 99%